# US 2026/0097009 A1 · Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097009 A1
- Document ID: US20260097009A1
- Status: Published application
- Kind: A1
- Application number: 19/363,255
- Filed: 2025-10-20
- Published: 2026-04-09
- Earliest claimed: 2021-03-19
- Assignees: Xwpharma Ltd.
- Applicants: XWPharma Ltd.
- Inventors: Daniel M. CANAFAX; William W. XIANG; Leonard BLUM; Jia-Ning XIANG
- Web page: https://patentgrep.com/patent/US20260097009A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.

## Claims

### Claim 1

A method of treating idiopathic hypersomnia in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising:
an immediate release component, wherein the immediate release component comprises from 2 g of γ-((L-valyl)oxy)butanoic acid to 7 g of γ-((L-valyl)oxy)butanoic acid; and
a modified release component, wherein the modified release component comprises from 6 g of γ-((L-valyl)oxy)butanoic acid to 16 g of γ-((L-valyl)oxy)butanoic acid.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immediate release component comprises immediate release microparticles.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the modified release component comprises modified release microparticles.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein
the immediate release component comprises immediate release microparticles; and
the modified release component comprises modified release microparticles.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutical composition comprises a suspension comprising the immediate release microparticles and the modified release microparticles.

### Claim 6

A method of treating idiopathic hypersomnia in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising:
an immediate release component, wherein the immediate release component comprises γ-((L-valyl)oxy)butanoic acid; and
a modified release component, wherein the modified release component comprises γ-((L-valyl)oxy)butanoic acid,
wherein a molar ratio of γ-((L-valyl)oxy)butanoic acid in the immediate release component to γ-((L-valyl)oxy)butanoic acid in the modified release component is from 1:1 to 1:10.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the immediate release component comprises immediate release microparticles.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the modified release component comprises modified release microparticles.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein
the immediate release component comprises immediate release microparticles; and
the modified release component comprises modified release microparticles.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutical composition comprises a suspension comprising the immediate release microparticles and the modified release microparticles.

### Claim 11

A method of treating idiopathic hypersomnia in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising:
an immediate release component, wherein the immediate release component comprises from 10 mol % to 40 mol % of γ-((L-valyl)oxy)butanoic acid; and
a modified release component, wherein the modified release component comprises from 60 mol % to 90 mol % γ-((L-valyl)oxy)butanoic acid,
wherein mol % is based on the total moles of γ-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the immediate release component comprises immediate release microparticles.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modified release component comprises modified release microparticles.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein
the immediate release component comprises immediate release microparticles; and
the modified release component comprises modified release microparticles.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises a suspension comprising the immediate release microparticles and the modified release microparticles.

### Claim 16

A method of treating idiopathic hypersomnia in a patient comprising administering to a patient in need of said treatment a therapeutically effective amount of a pharmaceutical composition comprising:
the immediate release component, wherein the immediate release component comprises from 10 wt % to 50 wt % γ-((L-valyl)oxy)butanoic acid, and
the modified release component wherein the modified release component comprises from 50 wt % to 90 wt % of γ-((L-valyl)oxy)butanoic acid,
wherein wt % is based on the total weight of γ-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the immediate release component comprises immediate release microparticles.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the modified release component comprises modified release microparticles.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein
the immediate release component comprises immediate release microparticles; and
the modified release component comprises modified release microparticles.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the pharmaceutical composition comprises a suspension comprising the immediate release microparticles and the modified release microparticles.
